During a Tuesday morning plenary session, Miriam Merad, MD, PhD, and a panel of cancer immunologists discussed some of the latest discoveries that are driving advances in cancer immunology research and therapeutic development.

During a Monday symposium, three researchers, including Quynh-Thu Le, MD, explored the potential of novel strategies to enhance the efficacy of radiation therapy in solid cancer at the individual level, and how these emerging therapies could help clinicians address the challenge of predicting therapeutic response.

In the second clinical trials plenary session at the Annual Meeting, positive results were reported from four more studies. Timothy A. Yap, MD, PhD, reported on a study that provides the first clinical proof-of-concept for effectively drugging the Hippo-YAP pathway.

Annual Meeting Program Committee Chair Robert H. Vonderheide, MD, DPhil, shares a few highlights from Tuesday’s schedule to help you plan your day.

During her presidential address Sunday evening, AACR President Lisa M. Coussens, PhD, FAACR, compared advances in cancer research to her own career journey and shared her hopes for the future of cancer research.

Five researchers, including E. Shelley Hwang, MD, MPH, described multiple avenues of research and discovery that demonstrate how cancer can be detected and assessed early to improve patient outcomes.

The last five forum sessions at the Annual Meeting will examine topics including biostatistics in clinical research, engaging diverse communities in clinical trials, and overcoming cancer workforce challenges.